How Ozempic Is Disrupting a $1.4 Trillion Industry

GLP-1 medications like Ozempic and Wegovy are transforming obesity treatment but they’re also creating a major headache for the U.S. life insurance industry, which wrote $1.4 trillion in premiums last year.

Here’s the issue: while these drugs are effective at improving health markers like blood pressure and weight, most patients stop taking them within a year. Once discontinued, those health gains often vanish quickly. Yet insurers, using outdated underwriting forms, still classify these individuals as low-risk leading to a phenomenon called mortality slippage.

What Is Mortality Slippage?

• It’s the gap between perceived and actual health risk.
• Underwriters may assign low-risk premiums based on improved lab results, unaware that the applicant’s health was temporarily boosted by GLP-1 use.
• If the patient quits the drug, their health may deteriorate, increasing the insurer’s payout risk.

According to Dr. Ashwin Sharma, this mismatch has more than doubled since 2019 and now affects about one in six policies. The challenge? Most underwriting forms don’t ask about GLP-1 use, and insurers are only beginning to adapt.

Some companies are starting to require disclosure of GLP-1 use or proof of long-term adherence before approving coverage. But until underwriting catches up, expect stricter applications, more denials, and rising premiums especially for high-BMI or diabetic applicants.

If you're building editorial modules around insurance, this is a goldmine for pairing behavioral economics with underwriting strategy.

GLP-1 drugs like Ozempic and Wegovy are reshaping obesity treatment but they’re also quietly destabilizing life insurance underwriting. Here's the crux of the issue:

• Underwriting Blind Spot: Most life insurance applications don’t ask about GLP-1 use. So applicants can present stellar lab results—lower blood sugar, improved blood pressure—without disclosing that these gains are drug-induced.
• Short-Term Adherence: Over half of GLP-1 users stop treatment within a year. Once they quit, those health improvements often vanish, but insurers have already locked in low premiums based on a temporarily healthier profile.
• Mortality Slippage Risk: This mismatch between perceived and actual risk—called mortality slippage—has more than doubled since 2019 and now affects roughly one in six policies. As Dr. Ashwin Sharma warns, “It just takes a couple thousand policies, and then you realize you may have a huge collapse.”

This is a textbook case of behavioral economics colliding with actuarial science. If you're building editorial modules around insurance, this is a prime opportunity to pair underwriting strategy with real-world risk modeling.

GLP-1 drugs like Ozempic and Wegovy are powerful tools for weight loss and metabolic health but they come with two major hurdles that lead many patients to quit:

• Cost Barrier: Monthly out-of-pocket costs range from $700 to $800 in the U.S., and many employers don’t cover them or require lengthy prior authorizations.
• Side Effects: As doses increase, nausea affects up to 50% of users, while vomiting, constipation, and abdominal pain hit another 10%.

When patients stop taking GLP-1s, their health markers like blood pressure and weight often rebound within months. But insurers may have already locked in low premiums based on those temporary improvements. This mismatch leads to mortality slippage, where the actual risk is higher than expected, resulting in costly payouts.

It’s a classic case of underwriting lagging behind medical innovation. Until insurers adapt, expect tighter screening, more denials, and rising premiums for high-BMI applicants even if they’re not on GLP-1s.

As GLP-1 drugs like Ozempic and Wegovy reshape obesity treatment, life insurers are scrambling to catch up. Some have begun asking about GLP-1 use or requiring proof of long-term adherence typically a year or more before approving coverage. But this is still far from standard practice.

Industry Response: Maintenance Over Monitoring

Rather than just tightening underwriting, insurers are exploring ways to improve patient retention:

• Longer prescription intervals to reduce dropout rates
• Proactive side-effect management to minimize nausea and discomfort

These strategies aim to stabilize health outcomes and reduce mortality slippage, but widespread adoption could take years.

What It Means for You

• Expect more denials as GLP-1 use becomes more common and underwriting remains outdated
• Premiums may rise for high-BMI or diabetic applicants—even if they’re not on GLP-1s—as insurers hedge against undisclosed use

If you're building editorial modules around this, it’s a prime opportunity to pair behavioral economics with underwriting strategy.

GLP-1 drugs like Ozempic and Wegovy are revolutionizing metabolic health, but they’re also exposing cracks in traditional life insurance underwriting. With outdated forms and limited visibility into medication adherence, insurers are flying blind leading to stricter applications, more denials, and rising premiums for high-risk profiles.

Dr. Ashwin Sharma’s advice is clear: “These are lifelong medications. We need to start treating them and viewing them as such.” That means both patients and insurers must rethink how risk is measured not just by lab results, but by long-term behavior.

If you're building editorial modules around this, it’s a prime opportunity to pair behavioral economics with underwriting strategy.